Endocrine treatment of benign prostatichypertrophy: Current concepts (Q34571957)

3 August 2017

1 reference

title

Endocrine treatment of benign prostatic hypertrophy: current concepts (English)

1 reference

3 August 2017

Endocrine treatment of benign prostatichypertrophy: Current concepts (English)

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

3 November 2022

main subject

prostatic hypertrophy

1 reference

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

3 November 2022

author name string

H. Matzkin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1702565

3 November 2022

Z. Braf

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1702565

3 November 2022

language of work or name

English

0 references

publication date

1 January 1991

1 reference

full work available at URL

3 August 2017

https://api.elsevier.com/content/article/PII:009042959180069J?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

https://api.elsevier.com/content/article/PII:009042959180069J?httpAccept=text/plain

3 November 2022

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

3 November 2022

1 reference

3 August 2017

volume

37

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

1-16

1 reference

Aromatase inhibitors and benign prostatic hyperplasia

3 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Balloon dilatation of the prostatic urethra. Work in progress

3 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The incidence of benign prostatic obstruction

3 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Natural history of benign prostatic hypertrophy

3 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The pathogenesis of benign prostatic hyperplasia

3 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Significance of signs and symptoms in benign prostatic hypertrophy

3 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The Natural History of Untreated “Prostatism”

3 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy

3 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Assessment of the Antihypercholesterolemic Drug, Probucol, in Benign Prostatic Hyperplasia

3 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy

3 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The Treatment of Benign Prostatic Hypertrophy with Flutamide (SCH 13521): A Placebo-Controlled Study

3 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

3 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

I. The Results of Double Castration in Hypertrophy of the Prostate

3 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

II. The Question of Castration for Enlarged Prostate

3 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

3 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Hormonal management of the benign obstructing prostate: use of combined androgen-estrogen therapy

3 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Nonsurgical Treatment of Human Benign Prostatic Hyperplasia

3 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Light Microscopic Stereological Analysis of the Normal Human Prostate and of Benign Prostatic Hyperplasia

3 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Aromatase inhibitors: their biochemistry and clinical potential

3 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The endocrinology and developmental biology of the prostate

3 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Benign prostatic hyperplasia. Universal problem among aging men.

3 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis

3 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog.

3 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate*

3 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Serum dihydrotestosterone in patients with benign prostatic hypertrophy

3 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

3 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Supranormal nuclear content of 5 alpha-dihydrotestosterone in benign hyperplastic prostate of humans

3 November 2022

41

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate

3 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate

3 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Increased ratio of 5 alpha-reductase: 3 alpha (beta)-hydroxysteroid dehydrogenase activities in the hyperplastic human prostate

3 November 2022

44

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Comparison of testosterone, 5alpha-dihydrotestosterone and 5alpha-adrostane-3beta, 17beta-diol metabolisms in human normal and hyperplastic prostates

3 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Serum steroids in normal males and patients with prostatic diseases

3 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Testosterone Metabolism of Fibroblasts Grown From Prostatic Carcinoma, Benign Prostatic Hyperplasia and Skin Fibroblasts

3 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding

3 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Biochemical investigations of separated epithelium and stroma from benign hyperplastic prostatic tissue

3 November 2022

50

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Androgen metabolism and actions in rat ventral prostate epithelial and stromal cell cultures

3 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Synergic inhibitory effects of the aromatase inhibitor 1-methyl-androsta-1, 4-diene-3, 17-dione and the antiandrogen cyproterone acetate on androstenedione-induced hyperplastic effects in the prostates of castrated dogs.

3 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results

3 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Origin of Estrogen in Normal Men and in Women with Testicular Feminization*

3 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Examination of the distribution of oestrogen receptor between the stromal and epithelial compartments of the canine prostate

3 November 2022

57

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The induction of prostatic hypertrophy in the dog with androstanediol

3 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Comparison of spontaneous and experimentally induced canine prostatic hyperplasia

3 November 2022

59

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Further Studies on Leydig Cell Function in Old Age

3 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of therapy on the concentration and occupancy of androgen receptors in human prostatic cytosol

3 November 2022

61

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of testosterone propionate on the prostate gland of patients over 45

3 November 2022

64

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A Study of the Effect of Stilbestrol Therapy on the Size of the Benignly Hypertrophied Prostate Gland

3 November 2022

66

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Estrogenic management of benign prostatism, including early and poor-risk cases. 7-year experience

3 November 2022

67

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of orchiectomy and estrogens of benign prostatic hyperplasia

3 November 2022

68

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate

3 November 2022

72

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate

3 November 2022

74

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review

3 November 2022

76

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

On the Mechanism of the Anti-androgenic Action ofFlutamide (α-α-α-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide)in the Rat

3 November 2022

77

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. II. Endocrinological analysis

3 November 2022

80

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Study of the effect of an anti-androgen (oxendolone) on experimentally induced canine prostatic hyperplasia. I. Morphological analysis

3 November 2022

81

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Evaluation of Depostat in prostatic adenoma on the ground of clinical and sphincterotonometric studies.

3 November 2022

83

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone

3 November 2022

84

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Therapy with progestational agents in advanced benign prostatic hypertrophy.

3 November 2022

85

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study

3 November 2022

87

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Treatment of Benign Prostatic Hypertrophy with Progestational Agents: A Preliminary Report

3 November 2022

88

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol acetate

3 November 2022

89

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of 17-α-hydroxyprogesterone 17-n-caproate on urine flow

3 November 2022

90

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Megestrol acetate in treatment of benign prostatic hypertrophy

3 November 2022

91

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Treatment of benign prostatic hypertrophy with medrogestone

3 November 2022

92

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of Megestrol Acetate (Megace®) on Steroid Metabolism and Steroid-Protein Binding in the Human Prostate

3 November 2022

94

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of 2-bromo-alpha-ergocryptine (CB154) administration of the hormone levels, organ weights, prostatic morphology and zinc concentrations in the male rat

3 November 2022

95

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Evidence for a Role of Prolactin in Prostate and Seminal Vesicle Growth in Immature Male Rats

3 November 2022

96

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of prolactin on human BPH epithelial cell proliferation

3 November 2022

98

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The efficacy of bromocriptine in benign prostatic hypertrophy. A double-blind study

3 November 2022

99

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of bromocriptine in benign prostatic hypertrophy and vesicosphincteric dynamics

3 November 2022

100

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Human benign prostatic hypertrophy: role of prostaglandin E2 and its relationships to bromocriptine therapy

3 November 2022

101

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The Effect of Bromocriptine in Patients with Benign Prostatic Hypertrophy

3 November 2022

102

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The pharmacological action of bromocriptine on the human prostate

3 November 2022

105

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro

3 November 2022

108

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

STUDIES ON PROSTATIC CANCER

3 November 2022

111

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Clinical applications of LHRH and its analogues

3 November 2022

113

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Involution of spontaneous benign prostatic hyperplasia in the dog under the influence of chronic treatment with a LHRH agonist

3 November 2022

114

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogs

3 November 2022

115

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases

3 November 2022

117

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Nafarelin acetate and benign prostatic hyperplasia

3 November 2022

118

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

3 November 2022

120

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy

3 November 2022

121

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters

3 November 2022

125

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Response of the benign hypertrophied prostate to treatment with an LHRH analogue

3 November 2022

126

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia

3 November 2022

129

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The hypocholesterolemic activity of orally administered polyene macrolides

3 November 2022

131

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Candicidin: Physiologic effect on prostate

3 November 2022

132

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A Double-blind Trial of the Effects of Candicidin on Patients with Benign Prostatic Hypertrophy

3 November 2022

135

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Efficacy of candicidin in benign prostatic hypertrophy

3 November 2022

137

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Antimycotics in hypertrophy of the prostate

3 November 2022

138

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Candicidin in treatment of benign prostatic hypertrophy

3 November 2022

139

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Candicidin treatment of prostatism: A prospective double-blind placebo-controlled study

3 November 2022

141

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia

3 November 2022

146

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Ketoconazole Therapy in Advanced Prostatic Cancer

3 November 2022

147

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Endocrine therapy: non-estrogenic pharmacological manipulation

3 November 2022

148

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of antiandrogen and/or antiestrogen blockade on human prostate epithelial and stromal cell protein synthesis

3 November 2022

149

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effects of androgen blockade with ketoconazole and megestrol acetate on human prostatic protein patterns

3 November 2022

150

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Interaction of Spironolactone and Digitalis with the 5α Dihydrotestosterone (DHT)1Receptor of Rat Ventral Prostate1

3 November 2022

151

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of bilateral adrenalectomy on induced benign prostatic hyperplasia in mice.

3 November 2022

152

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy

3 November 2022

153

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Cimetidine for hypertrophic prostate?

3 November 2022

156

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

5-Fluorouracil (5-Fu) in the treatment of prostatic hyperplasia

3 November 2022

158

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Observations with Bazoton in the management of prostatic hyperplasia.

3 November 2022

159

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts

3 November 2022

163

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia

3 November 2022

164

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The value of permixon in benign prostatic hypertrophy

3 November 2022

166

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Selective Retention of Dihydrotestosterone by Prostatic Nuclei

3 November 2022

169

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

3 November 2022

171

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Androgen of the Human Prostate

3 November 2022

172

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Prostate concentrations of endogenous androgens by radioimmunoassay

3 November 2022

173

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal

3 November 2022

174

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The role of the steroid-sensitive cation-dependent ATPase in human prostatic tissue

3 November 2022

175

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Stromal 5α-reductase activity is elevated in benign prostatic hyperplasia

3 November 2022

176

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues

3 November 2022

177

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of oestradiol-17beta and progesterone on the metabolism of testosterone by human prostatic tissue

3 November 2022

178

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effect of a new 5 alpha-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostate

3 November 2022

180

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors

3 November 2022

181

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate

3 November 2022

182

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The antiandrogenic action of 4-androsten-3-one-17 beta-carboxylic acid and its methyl ester on hamster flank organ

3 November 2022

183

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Inhibition of testosterone metabolism in the human prostate

3 November 2022

184

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Response of Rat Ventral Prostate to a New and Novel 5αa-Reductase Inhibitor

3 November 2022

185

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Differences in the mechanism of action of medrogestone and cyproterone acetate

3 November 2022

186

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 alpha-dihydrotestosterone in rat ventral prostate

3 November 2022

187

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effects of tamoxifen on the binding and metabolism of testosterone by human prostatic tissue and plasma in vitro

3 November 2022

189

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17 beta-oestradiol (E2), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with beni

3 November 2022

190

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer

3 November 2022

194

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Effects of cyproterone acetate on experimentally induced canine prostatic hyperplasia. A morphological and histochemical study

3 November 2022

195

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

In vitro effects of an aromatase inhibitor on 5 alpha-reductase activity in human hypertrophic prostatic tissue

3 November 2022

197

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate

3 November 2022

199

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

The Assessment of Prostatic Obstruction from Urodynamic Measurements and from Residual Urine

3 November 2022

201

1 reference

https://api.crossref.org/works/10.1016/0090-4295(91)80069-J

3 November 2022

Identifiers

1 reference

3 August 2017

1 reference